Wedbush Forecasts Weaker Earnings for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (TSE:FRX) – Analysts at Wedbush decreased their FY2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued on Thursday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their previous forecast of $0.08. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.12 EPS.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). The company had revenue of C$9.94 million for the quarter, compared to the consensus estimate of C$18.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%.

Fennec Pharmaceuticals Stock Down 1.6 %

FRX stock opened at C$5.98 on Monday. The firm’s 50-day moving average is C$6.61 and its two-hundred day moving average is C$8.37. The company has a market capitalization of C$163.61 million, a price-to-earnings ratio of 59.80 and a beta of 0.25. Fennec Pharmaceuticals has a 52 week low of C$5.76 and a 52 week high of C$15.43. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.